Clinical efficacy and body composition changes with sodium glucose cotransporter 2 inhibitor/glucagon-like peptide-1 agonist combination therapy in patients with type 2 diabetes mellitus-associated nonalcoholic fatty liver disease
If you are trying to decide between the two, our comparison page breaks down the clinical evidence for each medication
Obesity is no longer just a lifestyle issue its now globally recognized as a chronic, relapsing disease
The 2026 FDA Update What Happened Before In 2023 and 2024, the FDA told pharmacies to stop making BPC157 and TB500 because there was not enough safety data
Gallstones are hard deposits that form in your gallbladder, a small pear-shaped organ beneath your liver that stores bile for digestion
(Venkova et al., 2009.) The peptide boosts ghrelin levels, insulin levels, and cell synthesis